J&J's RYBREVANT Plus Chemotherapy Sets New Benchmark In EGFR Exon 20 Insertion NSCLC Survival

Johnson & Johnson said its bispecific antibody RYBREVANT, combined with chemotherapy, delivered the longest reported median overall survival in patients with EGFR exon 20 insertion mutation-positive non-small cell lung cancer. The clinical result strengthens RYBREVANT's efficacy profile in a difficult-to-treat NSCLC subgroup and could support its competitive positioning.